NCT03248674

Brief Summary

Patients with chronic kidney disease (CKD) before kidney transplantation require that obstructive coronary artery disease (CAD) is excluded, as cardiovascular complications are the leading cause of mortality in kidney transplant patients. However, in this patient population, the optimal method for the detection of obstructive CAD has not been identified. Noninvasive stress tests such as Dobutamine stress echocardiography or nuclear perfusion study have low diagnostic accuracy. CT fractional flow reserve measurement (CT FFR) is a novel non-invasive (FDA approved) imaging test to identify obstructive CAD. The goal of this project is to evaluate the diagnostic accuracy of CT FFR in the detection of obstructive coronary artery disease in patients with chronic kidney disease before kidney transplantation.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
26

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Aug 2017

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 10, 2017

Completed
4 days until next milestone

First Posted

Study publicly available on registry

August 14, 2017

Completed
14 days until next milestone

Study Start

First participant enrolled

August 28, 2017

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 24, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 24, 2020

Completed
Last Updated

January 6, 2022

Status Verified

December 1, 2021

Enrollment Period

2.4 years

First QC Date

August 10, 2017

Last Update Submit

December 16, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Diagnostic accuracy of CT FFR.

    Diagnostic accuracy of CT FFR (per vessel) in the detection of hemodynamically significant CAD as compared to invasive FFR derived from invasive coronary angiography (reference standard). Presence or absence of hemodynamically significant coronary artery disease in concordance between CT FFR and invasive FFR. Hemodynamically significant stenosis is defined as CT FFR value below 0.8.

    CT FFR and Invasive FFR are calculated immediately after coronary CT angiography and invasive coronary angiography

Interventions

CT FFRDIAGNOSTIC_TEST

CT FFR calculated the fractional flow reserve based on the data derived for a regular coronary CT angiography. Computation is based on development of an anatomic model of the epicardial coronary arteries for each case and calculating the maximum coronary flow during maximal hyperaemia based on a mathematical model incorporating fluid dynamics. These post-processing steps require quantification of the patient-specific myocardial mass as this allows for an estimation of the baseline coronary blood flow.

Eligibility Criteria

Age21 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Candidates for kidney transplantation without any residual kidney function and referred to cardiac evaulation.

You may qualify if:

  • Candidates for kidney transplantation on dialysis without any residual kidney function AND referred to invasive coronary angiography for cardiac evaluation
  • Referral to invasive coronary angiography is based on algorithm used at the Transplant Readiness Assessment Clinic (TRAC) at Stanford:
  • A. Diabetic Candidates older than 45 years.
  • B. Diabetic Candidates under 45 years old and any one of the following criteria is present:
  • a) 25 year History of Diabetes
  • b) 5 year Smoking History
  • c) Abnormal EKG (ST-T wave changes)

You may not qualify if:

  • Hemodynamically and clinically unstable condition (angina at rest, malignant arrhythmias)
  • Known ischemic heart disease (prior, documented myocardial infarction, prior stenting or coronary artery bypass graft surgery)
  • BMI\>30 kg/m2, or weight \>120 kg.
  • Atrial fibrillation or other arrhythmia, \>6 ectopic beats per minute
  • Known or suspected allergy to iodinated contrast medium
  • Pregnancy cannot be excluded

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Stanford Healthcare

Stanford, California, 94305, United States

Location

MeSH Terms

Conditions

Coronary Artery Disease

Condition Hierarchy (Ancestors)

Coronary DiseaseMyocardial IschemiaHeart DiseasesCardiovascular DiseasesArteriosclerosisArterial Occlusive DiseasesVascular Diseases

Study Officials

  • Dominik Fleischmann, M.D.

    Stanford Radiology

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor of Radiology

Study Record Dates

First Submitted

August 10, 2017

First Posted

August 14, 2017

Study Start

August 28, 2017

Primary Completion

January 24, 2020

Study Completion

January 24, 2020

Last Updated

January 6, 2022

Record last verified: 2021-12

Data Sharing

IPD Sharing
Will not share

Locations